ANAB AnaptysBio
- 23.410
- -2.820-10.75%
- 23.410
- 0.0000.00%
AnaptysBio News
AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
It's been a mediocre week for AnaptysBio, Inc. (NASDAQ:ANAB) shareholders, with the stock dropping 12% to US$23.41 in the week since its latest quarterly results. Revenues of US$7.2m crushed exp
The Analyst Landscape: 7 Takes On AnaptysBio
In the preceding three months, 7 analysts have released ratings for AnaptysBio (NASDAQ:ANAB), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates their rec
Wedbush Reiterates Outperform on AnaptysBio, Maintains $34 Price Target
Wedbush analyst David Nierengarten reiterates AnaptysBio with a Outperform and maintains $34 price target.
Wedbush: The AnaptysBio (ANAB.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $34.00.
Wedbush: The AnaptysBio (ANAB.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $34.00.
Wedbush Reaffirms Their Buy Rating on AnaptysBio (ANAB)
Buy Rating Affirmed for AnaptysBio Amidst Promising Pipeline and Strategic Financial Positioning
AnaptysBio GAAP EPS of -$1.64 Misses by $0.04
AnaptysBio Q1 2024 Adj EPS $(1.64) Misses $(1.57) Estimate, Sales $7.180M Beat $3.967M Estimate
AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.64) per share which missed the analyst consensus estimate of $(1.57) by 4.46 percent. The company reported quarterly sales of $7.180 million
AnaptysBio | 10-Q: Quarterly report
AnaptysBio 1Q Loss $43.9M >ANAB
AnaptysBio 1Q Loss $43.9M >ANAB
Press Release: Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update -- Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agon
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in GEMINI-2 through at least
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization From Amended Agreement With Sagard in Exchange for Additional Jemperli Royalties
Anaptys to receive $50 million upfront cash payment from Sagard HealthcarePrior agreement amended to now expire once Sagard receives a capped payoff of either $600 million if received by March 31, 2031 or $675 million if
Investors in AnaptysBio (NASDAQ:ANAB) From Five Years Ago Are Still Down 63%, Even After 35% Gain This Past Week
AnaptysBio, Inc. (NASDAQ:ANAB) has rebounded strongly over the last week, with the share price soaring 35%. But that is little comfort to those holding over the last half decade, sitting on a big l
Buy Rating Affirmed for AnaptysBio on Positive Development Outlook and Market Potential
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), AnaptysBio (ANAB) and LivaNova (LIVN)
Actym Therapeutics Appoints Thomas Smart As CEO >ANAB
Actym Therapeutics Appoints Thomas Smart As CEO >ANAB
AnaptysBio Initiated at Outperform by Leerink Partners
AnaptysBio Initiated at Outperform by Leerink Partners
AnaptysBio (ANAB.US) was first covered by Leerink Partners, which gave it an superior market rating, with a target price of $47.00.
AnaptysBio (ANAB.US) was first covered by Leerink Partners, which gave it an superior market rating, with a target price of $47.00.
Leerink Partners Initiates Coverage On AnaptysBio With Outperform Rating, Announces Price Target of $47
Leerink Partners analyst David Risinger initiates coverage on AnaptysBio with a Outperform rating and announces Price Target of $47.
Analysis
Price Target
No Data
